Loring Wolcott & Coolidge Fiduciary Advisors’s Idexx Laboratories IDXX Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61.7M	Sell	117,195 -5,109	-4%	-$2.87M	0.6%	41
2026 Q1	$68.9M	Sell	122,304 -1,741	-1%	-$1.12M	0.69%	36
2025 Q4	$86.2M	Sell	124,045 -3,066	-2%	-$2.09M	0.78%	34
2025 Q3	$81.2M	Sell	127,111 -4,572	-3%	-$2.78M	0.71%	32
2025 Q2	$70.6M	Sell	131,683 -2,092	-2%	-$1M	0.62%	38
2025 Q1	$57.1M	Sell	133,775 -684	-0.5%	-$297K	0.56%	41
2024 Q4	$57.5M	Sell	134,459 -375	-0.3%	-$164K	0.49%	44
2024 Q3	$61M	Sell	134,834 -4,373	-3%	-$2.12M	0.54%	42
2024 Q2	$69.5M	Sell	139,207 -1,070	-0.8%	-$537K	0.64%	36
2024 Q1	$67.3M	Sell	140,277 -1,523	-1%	-$832K	0.67%	39
2023 Q4	$73M	Sell	141,800 -8,564	-6%	-$4.02M	0.72%	34
2023 Q3	$63.1M	Sell	150,364 -4,253	-3%	-$2.12M	0.71%	35
2023 Q2	$77.7M	Sell	154,617 -99	-0.1%	-$47.4K	0.83%	33
2023 Q1	$77.4M	Buy	154,716 +1,060	+0.7%	+$507K	0.89%	32
2022 Q4	$62.7M	Buy	153,656 +577	+0.4%	+$224K	0.78%	35
2022 Q3	$49.9M	Buy	153,079 +398	+0.3%	+$146K	0.65%	39
2022 Q2	$53.5M	Buy	152,681 +542	+0.4%	+$221K	0.66%	38
2022 Q1	$83.2M	Sell	152,139 -241	-0.2%	-$127K	0.85%	33
2021 Q4	$100M	Sell	152,380 -1,627	-1%	-$1.02M	0.92%	34
2021 Q3	$95.8M	Sell	154,007 -193	-0.1%	-$130K	0.95%	33
2021 Q2	$97.4M	Buy	154,200 +4,494	+3%	+$2.48M	0.99%	32
2021 Q1	$73.3M	Buy	149,706 +1,869	+1%	+$936K	0.81%	37
2020 Q4	$73.9M	Buy	147,837 +202	+0.1%	+$90.4K	0.83%	36
2020 Q3	$58M	Sell	147,635 -117	-0.1%	-$43.3K	0.73%	36
2020 Q2	$48.8M	Sell	147,752 -624	-0.4%	-$181K	0.67%	37
2020 Q1	$35.9M	Buy	148,376 +1,827	+1%	+$477K	0.6%	38
2019 Q4	$38.3M	Buy	146,549 +465	+0.3%	+$123K	0.52%	43
2019 Q3	$39.7M	Sell	146,084 -841	-0.6%	-$234K	0.58%	43
2019 Q2	$40.5M	Sell	146,925 -310	-0.2%	-$76.4K	0.59%	45
2019 Q1	$32.9M	Buy	147,235 +1,585	+1%	+$327K	0.5%	48
2018 Q4	$27.1M	Buy	145,650 +8,873	+6%	+$1.82M	0.49%	49
2018 Q3	$34.1M	Sell	136,777 -328	-0.2%	-$79.6K	0.54%	44
2018 Q2	$29.9M	Sell	137,105 -2,155	-2%	-$444K	0.52%	45
2018 Q1	$26.7M	Sell	139,260 -405	-0.3%	-$74.7K	0.48%	48
2017 Q4	$21.8M	Sell	139,665 -1,483	-1%	-$233K	0.4%	55
2017 Q3	$21.9M	Buy	141,148 +4	+0%	+$632	0.42%	52
2017 Q2	$23.5M	Sell	141,144 -14,651	-9%	-$2.38M	0.47%	50
2017 Q1	$24.1M	Sell	155,795 -23,190	-13%	-$3.2M	0.5%	48
2016 Q4	$21M	Sell	178,985 -43,273	-19%	-$4.94M	0.47%	50
2016 Q3	$25.1M	Sell	222,258 -20,346	-8%	-$2.14M	0.57%	43
2016 Q2	$22.5M	Buy	242,604 +1,854	+0.8%	+$159K	0.52%	44
2016 Q1	$18.9M	Buy	240,750 +9,460	+4%	+$681K	0.44%	46
2015 Q4	$16.9M	Buy	231,290 +120,264	+108%	+$8.58M	0.42%	49
2015 Q3	$7.12M	Hold	111,026	–	–	0.18%	77
2015 Q2	$7.12M	Buy	111,026 +84,826	+324%	+$5.87M	0.18%	77
2015 Q1	$2.02M	Hold	26,200	–	–	0.05%	113
2014 Q4	$1.94M	Sell	26,200 -10	-0%	-$701	0.05%	114
2014 Q3	$1.54M	Sell	26,210 -160	-0.6%	-$10.1K	0.04%	118
2014 Q2	$1.76M	Hold	26,370	–	–	0.05%	115
2014 Q1	$1.6M	Sell	26,370 -1,340	-5%	-$79.8K	0.04%	119
2013 Q4	$1.47M	Hold	27,710	–	–	0.04%	127
2013 Q3	$1.38M	Sell	27,710 -280	-1%	-$13.5K	0.04%	125
2013 Q2	$1.25M	Buy	+27,990	New	+$1.22M	0.04%	139

Other funds holding IDXX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

MBI

Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

CGI

Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's IDXX Position: Q2 2026 in Review

Loring Wolcott & Coolidge Fiduciary Advisors reduced its Idexx Laboratories (IDXX) stake by 4.2% in Q2 2026, selling an estimated $2.87M and leaving 117,195 shares worth $61.7M. The position accounts for 0.6% of the portfolio, ranked #41.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in IDXX in Q2 2013 and has held it in 53 quarters since. The position peaked at $100M in Q4 2021. 715 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

Loring Wolcott & Coolidge Fiduciary Advisors held 117,195 shares of Idexx Laboratories worth $61.7M as of Q2 2026.
Loring Wolcott & Coolidge Fiduciary Advisors sold 5,109 Idexx Laboratories shares in Q2 2026, an estimated $2.87M.
Idexx Laboratories made up 0.6% of Loring Wolcott & Coolidge Fiduciary Advisors's portfolio in Q2 2026, its #41 holding.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Idexx Laboratories in Q2 2013 and has held it in 53 quarters since.
Loring Wolcott & Coolidge Fiduciary Advisors's Idexx Laboratories position peaked at $100M in Q4 2021.
715 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.